drug_type
RELEVANT_DRUG
intervention_type
monoclonal antibody
drug_description
Anti-CD38 monoclonal antibody that mediates ADCC/ADCP and direct proapoptotic signaling against CD38+ myeloma cells.
nci_thesaurus_concept_id
C90578
nci_thesaurus_preferred_term
Isatuximab
nci_thesaurus_definition
A humanized IgG1 monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. Isatuximab specifically binds to CD38 on CD38-positive tumor cells. This may trigger antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and apoptosis eventually leading to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.
drug_mesh_term
Isatuximab
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 anti‑CD38 monoclonal antibody that binds CD38 on myeloma cells, inducing antibody‑dependent cellular cytotoxicity and phagocytosis, complement‑dependent cytotoxicity, and direct pro‑apoptotic signaling; also inhibits CD38 ecto‑enzyme activity, depleting CD38+ malignant and immunosuppressive cells.
drug_name
Isatuximab
nct_id_drug_ref
NCT05675319